Journal article
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
Abstract
OBJECTIVES: The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
METHODS: Forty-four patients with newly diagnosed ANCA-associated vasculitis and renal …
Authors
Jones RB; Furuta S; Tervaert JWC; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V
Journal
Annals of the Rheumatic Diseases, Vol. 74, No. 6, pp. 1178–1182
Publisher
Elsevier
Publication Date
6 2015
DOI
10.1136/annrheumdis-2014-206404
ISSN
0003-4967
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntibodies, Monoclonal, Murine-DerivedAzathioprineB-LymphocytesCyclophosphamideDisease ProgressionDisease-Free SurvivalDrug Therapy, CombinationFemaleGlucocorticoidsGranulomatosis with PolyangiitisHumansImmunosuppressive AgentsKidney Failure, ChronicLymphocyte CountMaleMicroscopic PolyangiitisMiddle AgedRenal Insufficiency, ChronicRituximab